Clinical Research Efficiency Latin America: 4 Alarming Facts Sponsors Should Know
Clinical research efficiency Latin America has emerged as a strategic priority for sponsors and CROs seeking faster enrollment, more diverse patient populations, and investigators who are both trained to international standards and genuinely committed to trial success. While early perceptions held that healthcare systems in the region did not meet US and European standards, the reality today is fundamentally different. Latin America is now valued for its time and cost advantages, accessible and treatment naive patient populations, and a culture of investigator engagement that directly supports retention and data quality. According to the Mayo Clinic, clinical research that reflects real world population diversity produces findings that are more broadly applicable and more meaningful to global health outcomes.
What Is Driving Clinical Research Efficiency in Latin America
The foundation of clinical research efficiency Latin America is built on structural advantages that are difficult to replicate in North America or Europe. Most major Latin American cities are densely populated, which means each research site has access to a significantly larger potential patient pool. More patients per site translates directly into faster enrollment, easier follow up, and reduced travel costs for sponsors who would otherwise need to activate more sites across multiple geographies to achieve the same numbers.
Disease patterns in the region closely mirror those seen in the United States and Europe, with deaths from infectious diseases declining while cancer and cardiovascular disease mortality rates are rising. This epidemiological alignment makes Latin America suitable for a broad range of therapeutic area trials without requiring sponsors to adapt protocols significantly from those used in North American studies.
4 Alarming Clinical Research Efficiency Latin America Advantages
1. Patient Enrollment Is Faster and Less Competitive
Sponsors achieve their biggest time savings through enrollment efficiency in Latin America. Patients in the region tend to be more trusting of physicians and more willing to participate in research because access to structured medical care is genuinely valued. There are also fewer competing trials pursuing the same patient populations, which reduces the enrollment delays that have become routine in saturated US and European markets.
This clinical research efficiency Latin America advantage is particularly significant for sponsors running time sensitive studies where slow enrollment directly affects program timelines and costs.
2. Year-Round Research Is Possible Due to Seasonal Differences
Because the northern and southern hemispheres have opposite seasons, studies focused on seasonal diseases can be conducted year round by running trials in Latin America in conjunction with studies in North America or Europe. This capability is especially valuable for respiratory disease, allergy, and infectious disease research where enrollment windows are otherwise limited by seasonal variation.
3. Investigators Are Highly Trained and Motivated
Many investigators operating in Latin America have received training in the United States or Europe and are deeply familiar with Good Clinical Practice standards. Beyond technical competence, clinical research efficiency Latin America benefits from a culture of investigator commitment that directly supports site level performance. Investigators in the region are eager to participate in research and demonstrate strong engagement in site related activities, which reduces the monitoring burden on sponsors and improves data quality.
4. Medical Standards Are High and GCP Awareness Is Strong
Contrary to outdated perceptions, medical standards across major Latin American research centers are high and investigators are well versed in GCP requirements. FDA has approved numerous sites in the region, and the regulatory pathway to FDA approval is accessible. Sponsors who invest in appropriate preparation find that they can conduct medical research with quality results comparable to those achieved in the United States.
For a deeper overview of how Latin American trial dynamics compare globally, visit our related analysis of clinical trials in Latin America challenges and opportunities.
Challenges That Must Be Planned For
Clinical research efficiency Latin America does not mean a frictionless process. Importation logistics can be complex, particularly in countries with restrictive trade agreements. Some sites lack the infrastructure needed for certain specialized study types. Informed consent form requirements can be stringent depending on the country and the therapeutic area, and some study designs raise cultural sensitivities related to religious values that require protocol level consideration.
Sponsors and CROs who invest time in country selection, site qualification, and cultural preparation consistently find that these challenges are manageable and that the efficiency gains outweigh the additional planning requirements.
Why Diversity in Latin America Matters to Clinical Research
Latin America is one of the most ethnically and demographically diverse regions in the world. Running trials there allows sponsors to capture data from populations that are significantly underrepresented in North American and European research. Hispanics currently make up approximately 19% of the US population but account for a very small fraction of clinical trial participants. Building research infrastructure that reaches these communities is both a scientific imperative and a regulatory priority as FDA increasingly emphasizes diversity in trial enrollment.
Learn more about FOMAT’s commitment to diversity in clinical trials and how we work to ensure underrepresented communities have access to clinical research opportunities. Additional context on our approach to community based clinical research in the region is available in our overview of clinical research in Latin America.
FOMAT conducts Phase I through Phase IV clinical research across a national network of investigator sites throughout the United States. To learn more about active studies across therapeutic areas, visit our patient active studies page.